Announcements of drug trials and other treatment information


Postby vandy » Fri Oct 28, 2011 1:23 pm


Contact: Robert Mitchum
University of Chicago Medical Center
Drug treatment shows promise for brain blood vessel abnormality

Drug prevents cerebral cavernous malformation in mice; could replace surgery

A drug treatment has been proven to prevent lesions from cerebral cavernous malformation — a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke — for the first time in a new study.

The drug fasudil, which prevented the formation of lesions in a genetic mouse model of the disease, shows potential as a valuable new tool in addressing a clinical problem that is currently treatable only with complex surgery.

"The results are very exciting because they represent the first-ever evidence of a drug effect on the development of cavernous angiomas in living animals," said Issam Awad, MD, professor of surgery at the University of Chicago Medical Center and senior author of the study appearing in the journal Stroke. "The result was very dramatic. The prevalence of lesions went down significantly, and the lesions that developed in the mice were simpler and smaller and did not show any inflammation or bleeding."

Cerebral cavernous malformation (CCM), also known as cavernous angioma, occurs when small blood vessels of the brain grow abnormally large and irregular. The walls of these blood vessels can become stretched and thin, occasionally leaking blood into the brain and leading to hemorrhages, seizures, vision or hearing problems, and strokes.

CCM is estimated to occur in one out of 200 people, though the lesions may not always cause symptoms. Currently, when a CCM lesion is detected in an MRI of a patient, the only option is to wait and see whether it grows large enough to require brain surgery, Awad said.

"There is currently no treatment in clinical use to either prevent the formation or the maturation of these lesions," Awad said. "The way we deal with them now is we wait until a lesion gets bad or does something bad, and then we take it out."

Roughly one-third of CCM cases result from hereditary, familial forms of the disease, the most common of which was traced to a gene called CCM1 or KRIT1. By reducing this gene's activity, Awad's team in Chicago and geneticist Douglas A. Marchuk's team at Duke University successfully created CCM lesions in living mice. This model replicated familial CCM and allowed the testing of new treatments to prevent or reverse lesions.

In a parallel collaboration with Mark H. Ginsberg's group at the University of California, San Diego, the researchers proved that knocking down the CCM1 gene resulted in elevated activity of a signal called ROCK, which can make brain blood vessels "leaky." Further studies found that CCM lesion tissues resected from human patients and the mouse model also exhibited abnormally high ROCK activity. In light of these results, the researchers at the three institutions hypothesized that treatment with a drug inhibitor of ROCK might prevent CCM lesions from forming and rupturing.

Fasudil is the only specific ROCK inhibitor drug available for animal studies and human use, and has been tested for treatment of conditions such as angina and pulmonary hypertension. In the Stroke paper, first author David McDonald and colleagues tested whether a long-term treatment with fasudil could prevent lesion formation in CCM model mice.

After four months of treatment, genetically modified mice given fasudil displayed fewer and less severe lesions and fewer signs of hemorrhage and inflammation than similar mice given placebo treatment.

"This animal model and humans have lesions that are aggressive and symptomatic: They leak blood, they show inflammatory properties, and endothelial cells multiply or proliferate," Awad said. "None of these features were present in the fasudil-treated mice. It was like the lesion was chilled down and shrunk."

Fasudil is approved for clinical use in Japan for the treatment of a condition called cerebral vasospasm after aneurysm rupture, and it has been clinically well tolerated for that indication. In the U.S., the drug is not currently approved but has been tested in clinical trials for angina and pulmonary hypertension. If future experiments continue to support its effectiveness in CCM, Awad and colleagues hope to work with the drug manufacturers and the United States Food and Drug Administration to move this therapy to human clinical trials.

"This treatment approach will require validation and optimization in additional experiments before initiation of clinical trials; nevertheless, no other drug has ever before been shown to prevent lesion development, and this effect appears very promising," Awad said. "Our collaborative group is uniquely positioned with tools in hand to help develop this therapy."

Awad and colleagues are also hopeful that fasudil treatment might benefit sporadic forms of CCM, where they have detected increased ROCK activity. In the meantime, the fasudil results in mice offer hope that neurologists may soon have a preventative treatment that can ease the worries of patients with familial CCM.

"This treatment does not cure the disease," Awad said. "But if it is successfully translated to human therapy, it would be a bit like treating multiple sclerosis, where many treatments do not eliminate the primary disease trigger, but can muffle it, slow it down and make it not as serious, and therefore allow a patient to effectively live with the disease, as opposed to having the disease dictate their health."

The paper, "Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease," will be published online Oct. 27, 2011, by Stroke, and in the January 2012 print issue of the journal. In addition to Awad, study authors include Changbin Shi, Robert Shenkar and Feifei Liu of the University of Chicago Medical Center; David A. McDonald and Douglas A. Marchuk of Duke University Medical Center; and Rebecca A. Stockton and Mark H. Ginsberg of the University of California, San Diego.

Funding for the study was provided by the National Institutes of Health.

For more news from the University of Chicago Medical Center, follow us on Twitter at @UChicagoMed, or visit our Facebook page at www.facebook.com/UChicagoMed, our research blog at sciencelife.uchospitals.edu, or our newsroom at www.uchospitals.edu/news/.

Henk :ugeek:
User avatar
Posts: 1040
Joined: Thu Sep 30, 2010 10:02 pm


Postby Libby » Fri Oct 28, 2011 5:32 pm

Henk, I find that amazing. Thank you for bringing it to my attention.
multiple ccms in brain including thalamus and in brainstem. 9 bleeds . Large venous angioma and multiple large veins in the brain. Various lymphangiomas and hemangiomas in head.
User avatar
Posts: 571
Joined: Sat Sep 25, 2010 3:08 pm


Postby Vernswife » Fri Oct 28, 2011 6:22 pm

That is something ! I think I will have to read into it a little further :D Thanks Henk !!
My Husband has multiple angiomas with an associated venous angioma all located in his brainstem. Large bleed leaving him disabled December 2006, another bleed April 2012 in his medulla. He's still on the road to recovery
Posts: 102
Joined: Fri Nov 05, 2010 1:43 pm
Location: Arkansas


Postby Connie Lee » Fri Oct 28, 2011 6:53 pm

Dr. Amy Akers, our Chief Science Officer, has written a bit more about the work on our blog: http://www.angiomacommunity.org/blog/
Connie Lee
President and CEO, Angioma Alliance
On this journey since 2000, when my infant daughter was diagnosed.
To support Angioma Alliance, visit http://www.Angioma.org/Donate.
User avatar
Connie Lee
Founder, Angioma Alliance
Posts: 461
Joined: Sat Sep 25, 2010 2:41 pm
Location: Norfolk, Virginia


Postby Beckyinaz » Sat Oct 29, 2011 4:10 am

awesome news!!!
6 screws now! Right Frontal Lobe CM ~ Craniotomy by Dr. Spetzler December 2006 ~ Also diagnosed with a Chiari Malformation (6mm) 2007 watching and waiting on that one.
User avatar
Posts: 242
Joined: Sun Sep 26, 2010 11:33 pm
Location: Chandler, AZ


Postby Delfino » Sat Oct 29, 2011 2:33 pm

Very interesting. Definitely something to keep our eyes on.
Thanks, Henk
Posts: 43
Joined: Mon Aug 29, 2011 6:23 pm
Location: Seattle WA


Postby adelle » Sun Oct 30, 2011 5:53 pm

Thanks for posting, Henk. Wow!
One brainstem CA removed by Dr. Spetzler on 9/28/10. 2 CA's remain on the right frontal lobe but have not caused any problems that I know of.
Posts: 319
Joined: Mon Oct 04, 2010 2:49 pm


Postby Elizabeth » Mon Oct 31, 2011 2:42 am

Thanks Henk!!! Awesome news...progress.....hope, beautiful!!!
Diagnosed September '09 with one CM centered in the right insular cortex/basal ganglia. Saw many, many doctors and had surgery 12/10/10 with Dr. Spetzler. I am thrilled to have this bleeding thing out of my head even though I suffered a stroke during surgery. Have had/ continue to make an amazing recovery. http://www.thankfulforeveryday.blogspot.com
Posts: 1685
Joined: Mon Sep 27, 2010 6:49 pm
Location: Los Angeles


Postby penguru » Wed Sep 02, 2015 12:43 am

Anything new on Fasudil for an effective treament?
Posts: 8
Joined: Fri Aug 28, 2015 11:20 am


Postby Connie Lee » Wed Sep 02, 2015 3:56 am

Please watch Dr. Awad's presentation at the Angioma Alliance family conference this summer. He discusses Fasudil as well as a number of other potential medications. It starts at 1:18:40. https://www.youtube.com/watch?v=s9o4iXKkmEA
Connie Lee
President and CEO, Angioma Alliance
On this journey since 2000, when my infant daughter was diagnosed.
To support Angioma Alliance, visit http://www.Angioma.org/Donate.
User avatar
Connie Lee
Founder, Angioma Alliance
Posts: 461
Joined: Sat Sep 25, 2010 2:41 pm
Location: Norfolk, Virginia

Return to Drug Trials

Who is online

Users browsing this forum: No registered users and 1 guest